How we work.

We engage with a small number of research groups at a time. Selection starts from the science: is the underlying work genuinely competitive at a global level, is there a path through the patent and regulatory landscape, and is there a market large enough to absorb a serious company. We say no often, and we say no early.

For each piece of research we take on, we produce a written commercial thesis: the global competitive landscape, the IP position of competing approaches, the regulatory pathway, the realistic buyers and partners, the team the company would need, and the capital plan from formation through Series A. The thesis is something the researcher and the university can read, push back on, and decide what to do with.

A scientific founder is necessary but rarely sufficient. Two scenarios shape how we assemble the team:

Technical-CEO scenario. When the scientific founder has both the temperament and the appetite to run the company, we build the commercial bench around them — a senior commercial lead, finance, and operating partners drawn from our operator network.

External-CEO scenario. When the scientific founder prefers to stay close to the research, we match the company to an experienced CEO from our network — operators, often from the diaspora communities of our target geographies, who have built companies at scale and want to run one built around frontier research from their country of origin.

For the analytical and institutional work we do before and around formation, we take a 5% common-equity stake in the company at incorporation and a $500k MFN SAFE that converts at the first priced round.

Worked example. A company incorporates with 10M shares. field/lab holds 500k shares (5%). The scientific founder and the originating university hold the rest under terms negotiated with the TTO. At a $20M post-money seed priced round, the $500k SAFE converts on MFN terms alongside the lead investor. The structure is designed to be readable to any international growth investor and to keep the founder and university meaningfully on the cap table.

Delaware C-corp by default, because that is the structure international growth capital underwrites without friction. We support an in-country incorporation when the science, the regulatory path, or the customer base makes it the right call — and we structure the relationship between the in-country entity and any international holding company so that capital can still flow.

We are not a consulting firm. We do not produce reports for a fee. We do not take on engagements where company formation is not the realistic end. We do not ask for exclusivity on a researcher's future work. We do not run accelerator cohorts.

We are in our first phase. Active work is concentrated in India, with a small initial group of researchers in materials science, energy storage, and water and environmental engineering. Brazil and South Africa are next. We go deep with a small number of researchers and institutions, and the relationships that start in this phase shape what the institution becomes.